4.06

5.36% -0.23

After Hours: 4.13 0.07 +1.72%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $4.06, with a volume of 2.58M. It is down -5.36% in the last 24 hours and up +4.91% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Previous Close:

$4.29

Open:

$4.295

24h Volume:

2.58M

Relative Volume:

0.77

Market Cap:

$448.90M

Revenue:

$34.86M

Net Income/Loss:

$-103.80M

P/E Ratio:

-3.4279

EPS:

-1.1844

Net Cash Flow:

$-96.02M

1W Performance:

-5.58%

1M Performance:

+4.91%

6M Performance:

+89.72%

1Y Performance:

+104.02%

1-Day Range:

$3.91

$4.295

1-Week Range:

$3.725

$4.425

52-Week Range:

$1.6901

$5.17

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

104

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	4.06	474.33M	34.86M	-103.80M	-96.02M	-1.1844
VRTX Vertex Pharmaceuticals Inc	485.39	126.01B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	70.03B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	56.56B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	40.63B	742.00K	-1.37B	-1.07B	-7.0731

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

Jul 10, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 10, 2026

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jul 10, 2026

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 10, 2026

Jul 08, 2026

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 08, 2026

Is C4 Therapeutics (CCCC) stock outpacing its medical peers this year? - MSN

Jul 08, 2026

C4 Therapeutics (CCCC) Status Update Summary - Quartr

Jul 08, 2026

Jul 07, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 07, 2026

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jul 07, 2026

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire

Jul 07, 2026

Jul 06, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jul 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 06, 2026

Jul 03, 2026

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 03, 2026